ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2020 and Provide a Corporate Strategic Update
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) is set to release its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020. Following the announcement, the company will hold a conference call and webcast at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide a corporate strategic update. The company specializes in automated cell processing tools and services, primarily for the cell and gene therapy sector.
- ThermoGenesis is a leader in automated cell processing for CAR-T therapies.
- The upcoming release of financial results may indicate positive performance metrics.
- No specific financial metrics or performance guidance were provided in the PR.
RANCHO CORDOVA, Calif., Nov. 5, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 and provide a corporate strategic update on Thursday, November 12, 2020 after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.
To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts.
A webcast replay will be available on ThermoGenesis' website for three months by visiting the Investor page of the Company's website at www.thermogenesis.com.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original content:http://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-third-quarter-ended-september-30-2020-and-provide-a-corporate-strategic-update-301167016.html
SOURCE ThermoGenesis Holdings, Inc.
FAQ
When will ThermoGenesis announce its third-quarter financial results?
What time is the ThermoGenesis conference call scheduled for?
Where can I access the webcast of ThermoGenesis' conference call?
What is the focus of ThermoGenesis Holdings, Inc.?
